Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Results of Operations and Financial ConditionItem 2.02.
On August3, 2017, we issued a press release announcing our results for the quarter ended June30, 2017 and will conduct a previously announced, publicly available conference call to discuss those results. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on the websites referenced in the press release is not incorporated herein.
This information and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 2.02. | Financial Statements and Exhibits. |
| (d) | The following exhibit is included in this report: |
|
ExhibitNo. |
Description |
| 99.1 | Press release dated August3, 2017 |
INFINITY PHARMACEUTICALS, INC. ExhibitEX-99.1 2 d413441dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Infinity Provides Company Update and Reports Second Quarter 2017 Financial Results – Phase 1 Clinical Study Evaluating IPI-549 as a Monotherapy and in Combination with Opdivo® Advancing – – IPI-549 Monotherapy Dose Escalation Completed and Monotherapy Expansion Initiated – – Dose Escalation Evaluating IPI-549 in Combination with Opdivo Ongoing; Combination Expansion Expected to Initiate in the Second Half of 2017 – Cambridge,…To view the full exhibit click here
About Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
